Perinatal asphyxia is a cause of significant neonatal morbidity worldwide. Lack of oxygenation and perfusion to the neonatal brain leads to energy failure and cell death. Currently, therapeutic hypothermia is the standard of care for term infants with hypoxicischemic encephalopathy, but as it has shown only modest effects on survival and morbidity, additional neuroprotective agents are needed. Erythropoietin has been extensively studied as a neuroprotective agent for infants who suffer a hypoxic-ischemic brain injury. It has multiple mechanisms of action, in both preventing cell death and promoting tissue repair. Studies have progressed over time from in vitro to in vivo studies, first in animals and now in humans, with several Phase I/II trials completed and Phase III trials underway. As therapeutic hypothermia has become the standard of care in treating term infants with hypoxic-ischemic encephalopathy, studies must now evaluate other neuroprotective agents, including erythropoietin, used in concert with therapeutic hypothermia. Erythropoietin has shown promise as a neuroprotective agent in animal and human models, both alone and together with hypothermia.
Mechanisms of cell death
Three mechanisms of cell death can occur in response to hypoxic-ischemic injury: necrosis, apoptosis, and autophagy. These cell death programs are complex, interrelated, and involve signaling pathways which can potentially be interrupted or modified, allowing for targeted neuroprotective strategies. 10 Necrotic cell death tends to occur early following HIE. It is characterized by profound cellular swelling leading to cell rupture, membrane disintegration, and release of intracellular contents. 5 Necrotic cell death requires less energy than apoptosis or autophagy, but still involves activation of specific signaling pathways. 11, 12 Neuronal necrosis that occurs in the context of excitotoxicity and hypoxic-ischemic injury is mediated by membrane depolarization caused by glutamate-triggered influx of calcium into the cell. Necrosis occurs predominantly in sites of profound energy deprivation, such as the core of an ischemic region, and is responsible for much of the immediate cell death during the first phase after injury, but there is a continuum between necrotic and apoptotic cell death. 13, 14 In contrast to necrosis, apoptosis is a form of programmed cell death characterized by immunologically silent cell shrinkage with nuclear pyknosis and intact plasma membranes. 5 It can be activated by intrinsic or extrinsic pathways. The intrinsic, or mitochondrial, pathway depends on the balance of antiapoptotic proteins (such as Bcl-2 and Bcl-xL) and proapoptotic proteins (such as BAX and BAD). 15, 16 Apoptosis can also be triggered by external signals such as Fas ligand and tumor necrosis factor-alpha (TNF-α) activation of proapoptotic receptors on the cell surface, which is known as the extrinsic pathway. Proapoptotic proteins cause permeabilization of the mitochondrial membrane, allowing factors including cytochrome c to be released into the cytosol, leading to apoptosis. 17 Neuroapoptosis following hypoxic-ischemic injury typically occurs in the ischemic penumbra during the secondary phase of brain injury, making this pathway an excellent target for neuroprotection. 10, 18 Autophagy is a homeostatic process by which unwanted proteins and damaged organelles are eliminated from cells. It is a catabolic process involving intracellular degradation of cytosolic proteins and organelles by autophagosomes, which fuse with lysosomes to form autolysosomes. 10 Autophagy is now recognized as a distinct mechanism of cell death that is interrelated to both necrosis and apoptosis. 19 There are several proposed mechanisms for the role of autophagy in cell death following hypoxic-ischemic injury, including as an independent mechanism and as a trigger for apoptotic cell death. 10 The mechanism of cell death that predominates in hypoxic-ischemic injury is influenced by characteristics of the individual including age (neonates are more sensitive to apoptosis than adults, and the location of calcium permeable membrane receptors switches from white matter to gray matter over time), sex (different specific pathways predominate in males compared to females), and other factors, such as energy availability. [20] [21] [22] Many cells die from hybrids of multiple pathways (such as apoptosis and necrosis or apoptosis and autophagy), as there are significant interconnections between pathways. 23, 24 The overlap in cell death pathways makes identifying targets for neuroprotective agents complex, because cell death can proceed down an alternative pathway if one pathway is inhibited. 10 can have negative effects. [25] [26] [27] [28] As understanding of the complex interactions between mechanisms of cell death and survival improves, neuroprotective strategies may include use of multiple complimentary agents, either to target different pathways or to use one drug to extend the therapeutic window for another.
Therapeutic hypothermia
Therapeutic hypothermia has become the standard of care treatment for HIE. 3, 29 It has multiple neuroprotective effects, including decreased energy depletion, inhibition of glutamate release and decreased impairment in glutamate reuptake, deceased free radical generation and inflammation, and blockade of pathways leading to apoptosis ( Figure 1 ). 5 It has been shown in trials to reduce the risk of death or major neurodevelopmental disability by approximately 50% with a number needed to treat of 7-9. 3, 30 As hypothermia has become the standard of care, research into other neuroprotective agents, particularly in humans but also in animal models, has shifted from study of a neuroprotective agent alone to investigation of the combined effects of the agent along with hypothermia.
Erythropoietin
Erythropoietin (Epo) is a 30.4 kDa hematopoietic cytokine that was originally recognized for its role in erythropoiesis.
It is produced primarily in the kidney of adults and the liver of fetuses, although Epo production also occurs in the brain, testis, and placenta. 31, 32 Endogenous Epo is required for normal brain development, function, and repair. Epo is primarily produced by astrocytes but can also be detected in oligodendrocytes, neurons, endothelial cells, and microglia. [33] [34] [35] [36] [37] [38] In the setting of hypoxia-ischemia, Epo receptors (EpoRs) in neurons, astrocytes, and microglia are massively upregulated. 39, 40 Increased Epo expression follows, via hypoxia-mediated stabilization of neuronal transcription factor hypoxia-inducible factor 1α, if the insult is of sufficient duration. 41, 42 Hypoxia-inducible factor-2 (HIF-2) has also been found to regulate the production of Epo in response to hypoxia in many tissues, though its precise role is less clear. [43] [44] [45] [46] In the absence of Epo-EpoR binding, cells are predisposed to apoptosis, while, in the presence of Epo, cells are preserved. 47, 48 This creates an important rationale for exogenous Epo administration, given that brain injury can occur after brief but catastrophic insults, such as placental abruption or cord accidents, which are insufficient to stimulate an increase in endogenous Epo synthesis. 49
Mechanisms of action of Epo
Epo binds to the EpoR homodimer, which activates Jak2 kinase to phosphorylate Jak2 and EpoR ( Figure 2 ). [50] [51] [52] 
Figure 1
Comparison of mechanisms of neuroprotection between therapeutic hypothermia and erythropoietin (epo). Notes: Mechanisms of brain injury and recovery after injury are listed. Therapeutic hypothermia and epo have many similar mechanisms of action, but epo has additional effects of prevention of necrosis and promotion of angiogenesis and neurogenesis beyond hypothermia alone. This activates multiple signaling cascades, including MAPK/ ERK, PI3K/Akt, Stat5, and NF-κB. 53, 54 NF-κB and Stat5 move into the nucleus and act as transcription factors in the production of Bcl-2 and Bcl-xL, which are antiapoptotic proteins. 40, 55 Epo also inhibits the function of Bax and Bad, which are proapoptotic, via AKT. The balance of these proteins determines whether a cell undergoes apoptosis. 40 In addition to the EpoR homodimer, other receptor complexes have been implicated in the neuroprotective effects of Epo. In particular, the common beta receptor (CβR)-EpoR heterodimer has been found in some studies to be essential in Epo neuroprotective abilities, but other studies have not confirmed these findings. 56, 57 These signaling pathways have multiple downstream neuroprotective and neurotrophic effects.
Epo appears to have both acute and long-term effects following brain injury ( Figure 1 ). Through multiple mechanisms, Epo decreases cell death acutely and also promotes cell and tissue repair, affecting many components of the neurovascular unit. Many studies have demonstrated Epo's antiapoptotic effects. 50, 53, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] Additionally, Epo has also been shown to have anti-inflammatory, neurotrophic, and antioxidant properties, along with having a role in promoting angiogenesis, neurogenesis, and oligodendrogenesis. 47, [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] Epo may protect the brain from edema by upregulation of aquaporin channels. 81 Epo also increases reticulocytosis in preterm infants, which in turn increases iron utilization. When iron is unbound, it can produce free radicals that cause oxidative injury, so, by increasing iron utilization, Epo may secondarily decrease injury. 82, 83 
Animal and human studies of Epo
The effects of Epo on neonatal brain injury have been studied in multiple animal models (Table 1) , most commonly in the rat model of unilateral carotid ligation followed by hypoxia (Vannucci model) and the middle cerebral artery occlusion model. 84, 85 These models are commonly used to produce gray matter injury similar to that seen in term infants who experience hypoxic-ischemic injury or perinatal stroke, respectively. Animal models have been used both to demonstrate Epo's neuroprotective effects on gross and histological brain injury and neurobehavioral outcomes and to elucidate the mechanism of neuroprotection. There is some variability in the results of these studies, likely related to variability in methodology, including duration of hypoxia/ischemia; timing, dose, and frequency of Epo administration; and timing of the outcome studied. Overall, however, Epo has been shown Notes: epo production is upregulated after hypoxia via stimulation of HiF-1, but it can also be given exogenously. epo binds to the epo receptor (epoR) homodimer, causing JAK2 kinase phosphorylation of JAK2 and the epoR, which triggers a signaling cascade that involves STAT5, NF-κB, PI3K/AKT, and MAPK/ERK. Together, this leads to production of antiapoptotic proteins, including Bcl-2 and Bcl-xL, and also inhibition of proapoptotic proteins, including Bad and Bax. The balance of proapoptotic and antiapoptotic proteins affects release of substances such as cytochrome c from the mitochondria which then leads to apoptosis. to be protective over a wide range of doses, in multiple animal models, by multiple investigators (see Table 1 ). As hypothermia became the standard of care for neonates with HIE, Epo began to be incorporated in animal studies of HIE. 49, 86, 87 Fan et al published a study in 2012 comparing no treatment, hypothermia alone, Epo alone, and hypothermia + Epo on brain injury and behavior in rats subject to a hypoxicischemic insult using the Vannucci model. 87 Hypothermia in this study consisted of 3 hours at 32.5°C-33°C immediately after the hypoxic period was complete. Epo was dosed at 5,000 U/kg given intraperitoneally immediately after hypothermia and repeated 24 and 48 hours later. The investigators found that administration of Epo alone modestly improved behavioral outcomes at 2 and 5 weeks post-injury (measured using the cylindrical rearing test) but had no effect on histologic brain injury. Similarly, Epo in addition to hypothermia had a mildly additive effect on hypothermia alone in improving behavioral outcomes but no additive effect for histological injury. Interestingly, the authors found that the neuroprotective effects of hypothermia were more pronounced in female animals, while Epo did not have sex-specific effects. In the same journal, Fang et al published a similar study evaluating the effects of Epo and hypothermia on neonatal rats subjected to hypoxic-ischemic injury using the Vannucci model. 86 In this study, therapeutic hypothermia consisted of 8 hours at 32°C and Epo was dosed at 1,000 U/kg, given immediately after injury but prior to hypothermia and repeated at 24 hours and 7 days post-injury. The authors found no differences between untreated animals and animals treated with hypothermia, Epo, or both in either histopathological or behavioral outcomes other than improved histopathological outcomes in male animals treated with Epo. Traudt et al completed a study in 2013 comparing hypothermia alone to hypothermia + Epo in a nonhuman primate (pigtail macaque) model of perinatal asphyxia. 49 The macaques were exposed to 15 or 18 minutes of umbilical cord occlusion and were then treated with 72 hours of therapeutic hypothermia at 33.5°C with or without Epo or were untreated. Epo was initially dosed intravenously at 3,500 U/kg for one dose, followed by three doses of 2,500 U/kg given at 24 and 72 hours and 7 days post-injury, but was then switched to 1,000 U/kg for all four doses based on pharmacokinetic data. The authors found that, among macaques exposed to umbilical cord occlusion, there was a 44% incidence of death or moderate-to-severe cerebral palsy in the untreated animals and a 43% incidence in the animals treated with hypothermia alone compared to a 0% incidence in the hypothermia + Epo group. Animals treated with hypothermia + Epo also showed improvement Rat/P7/MCAO 1,000 U/kg ip at 15 minutes, 1 day, and 2 days post-injury increased brain weight at 6 and 12 weeks post-injury, decreased infarct volume at 6 weeks (greater effect in females than males), increase in size of lesion by 12 weeks in epo-treated males but not females, improved neurobehavioral outcomes at 6 and 12 weeks post-injury (again greater effect in females)
HIF-1
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Rat/P10/MCAO ×45 minutes epo 5,000 U/kg ×1 after injury Decreased tissue loss overall in brain, decreased number of astrocytes, and increased neurogenesis in damaged striatum, without changes in subventricular zone volume or density of newly generated cells in injured striatum at 6 weeks post-injury 
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Pet and Juul in motor and cognitive outcomes, cerebellar growth, and diffusion tensor imaging (DTI) measures. These three studies clearly have disparate results regarding the efficacy of both hypothermia and Epo. This variability could be related to many factors, including differences in the models used, Epo dosing, and the duration and degree of hypothermia. 88 Traudt's study is the first study of Epo and hypothermia in a nonhuman primate model of HIE. Large-animal models of brain injury offer both advantages and disadvantages compared to small animal models. Large animals (sheep, piglets, nonhuman primates) are expensive and require more resources for their care, thus it is not possible to include the same number of subjects as are typically included in small-animal studies. However, in many ways, their brains are more similar to those of humans. Large animals possess a gyrencephalic brain, a white to gray matter ratio that better approximates that of humans, and similar vascular patterns to humans and they can be monitored and cared for in a manner similar to neonates in an intensive care unit. 89
Human studies of Epo
In the past 5 years, several studies on the neuroprotective effects of Epo on human infants with HIE have been published ( Table 2 ). The initial study by Zhu et al in 2009 compared Epo to supportive care in infants with moderateto-severe encephalopathy. 90 Epo was dosed at either 300 or 500 U/kg and given subcutaneously immediately following injury and repeated every other day for 2 weeks intravenously. The authors demonstrated decreased incidence of moderate-to-severe disability or death at 18 months of age in infants given either of the two doses of Epo, particularly in infants with moderate compared to severe HIE, without adverse hematopoietic side effects. The second study, by Elmahdy et al in 2010, compared Epo to supportive care in infants with mild-to-moderate HIE. 91 Epo was dosed at 2,500 U/kg subcutaneously, started within 4-6 hours of injury, and repeated daily for five total doses. These authors also demonstrated improved outcomes in infants treated with Epo, including decreased seizure activity, decreased endogenous nitric oxide production, and improved neurodevelopmental outcomes up to 6 months. The third study, by Wu et al in 2012, was a Phase I/II study of the safety and pharmacokinetics of Epo at escalating doses in infants with HIE being treated with therapeutic hypothermia. 92 Doses ranged from 250 to 2,500 U/kg and were administered intravenously, starting at less than 24 hours of age and continuing every 48 hours for up to six total doses. The authors showed that dosing at 1,000 U/kg produced plasma concentrations similar to those found to be neuroprotective in animals and was well tolerated. At mean age 22 months, infants who received Epo exhibited a relatively low rate of moderate-to-severe disability, even in the setting of significant brain injury. 93 The most recent study, by El Shimi et al in 2014, examined whether a single dose of Epo was as safe and effective as hypothermia in treating HIE, given that hypothermia was not available in many lower-resource nations, despite being the standard of care for HIE in developed nations. 94 Epo was dosed at 1,500 U/kg given subcutaneously on day 1 of life. Hypothermia was accomplished using cold packs to maintain 
Epo dosing and adverse effects
The optimal dosing regimen in human neonates is unknown. Epo is ineffective at promoting neuroprotection at very low doses and may cause harm at very high doses. 82, 95 Kellert et al's dose comparison study in rats demonstrated that three doses of 5,000 U/kg resulted in the most consistent neuroprotection with the lowest total dose exposure. 62 Traudt et al's study, which showed strong benefits of Epo when used in conjunction with hypothermia, found that dosing hypothermic macaques at 1,000 U/kg produced similar pharmacokinetic parameters to rats dosed at 5,000 U/kg. 49 Interestingly, these authors noted that a dosing regimen in hypothermic macaques produced a 25% higher peak Epo concentration than expected based on pharmacokinetic data obtained in normothermic human neonates, suggesting that hypothermia alters Epo's pharmacokinetics. Wu et al's pharmacokinetic study of Epo in human neonates undergoing therapeutic hypothermia for HIE also found that 1,000 U/kg of Epo produced similar pharmacokinetic parameters as doses that have been found to be neuroprotective in animal models. 92 The significance and severity of adverse effects related to Epo administration also remain controversial. As Epo is used primarily as an erythropoietic agent, it certainly has effects on red blood cell formation. Polycythemia has not been seen in trials of neuroprotection in term infants, and two trials did not find a significant difference in hematocrit and number of red blood cell transfusions between treated and untreated infants, although Zhu et al's trial did show that use of Epo prevented the decrease in hematocrit over time seen in control and hypothermia-only infants. [90] [91] [92] [93] [94] In adults, Epo has been associated with an increased risk for hypertension, but this has not been the case in neonates. 83, [96] [97] [98] [99] In premature infants, Epo has been linked to several possible adverse effects. Early studies demonstrated a risk of neutropenia after treatment with Epo, but this has not been confirmed in later studies of erythropoietic or neuroprotective dosing of preterm infants. 83, [97] [98] [99] [100] There has also been concern about increased risk of retinopathy of prematurity in preterm infants treated with Epo, particularly early in life, but the data are conflicting and this is not relevant to term infants. 98, 99, [101] [102] [103] [104] In one retrospective study, an increased risk of cutaneous hemangiomas was reported with Epo exposure in preterm infants, but, as cutaneous hemangiomas are common in preterm infants, a causal relationship has not been established. 83, [105] [106] [107] [108] There are theoretical concerns regarding clotting abnormalities in infants treated with both Epo and therapeutic hypothermia. Hypothermia has negative effects on hemostasis and leads to increased risk of disseminated intravascular coagulation. 109, 110 Epo may also affect clot formation, as use of Epo has been associated with increased risk for thromboembolic events in adults with strokes. 111 At this time, no studies of normothermic or hypothermic neonates treated with Epo have demonstrated increased risk of clotting abnormalities, but we must continue to be vigilant about this potential adverse effect. Overall, significant adverse effects have not been seen in term or preterm infants treated with Epo.
Limitations of studies to date Animal models
The animal models described previously all attempt to reproduce hypoxic-ischemic injury in term infants. 112 While these models can simulate the human neonatal experience, they are not exact reproductions. Infants that meet clinical criteria for HIE can have had very different antenatal and perinatal experiences. HIE may be caused by a single acute event, such as a placental abruption or umbilical cord prolapse; a more chronic process like intrauterine growth restriction or infection; or a combination of events, such as a difficult delivery in a stressed infant who does not tolerate delivery well due to maternal chorioamnionitis or longstanding placental insufficiency. Thus, infants with HIE who meet entry criteria for a study may in fact have disparate mechanisms of injury, which likely helps to explain variability in response to treatments and, therefore, outcomes. Additionally, it is likely that infants with mild, moderate, and severe HIE will respond differently to neuroprotective therapies. 3, 90 Many of the studies on the neuroprotective effects of Epo following HIE use the Vannucci model, which models acute, severe hypoxic ischemic brain injury, but does not reflect more chronic or combined inflammatory and hypoxic injuries. Thus, it is important to glean information from a wide variety of animal models and, as clinical trials are planned, to target 
Human studies
There is currently a paucity of human trials available from which to assess the efficacy of Epo neuroprotection for HIE. Phase I/II trials have been undertaken to establish rudimentary safety, pharmacokinetics, and feasibility of larger studies and have provided limited long-term outcome data. Because of the nature of these studies, there is also significant heterogeneity in study design, with Epo doses ranging from 250-2,500 U/kg, dosing intervals ranging from 24-48 hours, and dose numbers ranging from one to seven. Despite these limitations, these studies have laid the groundwork for future Phase III studies in which the safety and efficacy of Epo neuroprotection can be rigorously tested.
Conclusion
In the past 5 years, there has been a significant advancement in treatment of HIE. Therapeutic hypothermia has been proven to improve outcomes, with a number needed to treat of 7. Despite this, infants with moderate-to-severe HIE who receive hypothermia still experience high rates of death (26%) and, among survivors, developmental delay (23%), cerebral palsy (19%), deafness (4%), and blindness (6%). The overall rate of death or major disability despite hypothermia thus remains unacceptably high (48%). 4 Adjuvant therapies are therefore needed to further improve outcomes.
As we further our understanding of how cells die after neonatal hypoxic-ischemic brain injury, we can develop new neuroprotective strategies that promote or inhibit specific pathways. The complex and interconnecting pathways of cell death illustrate the need to approach neuroprotection from multiple angles. Several agents, including Epo, have shown promise as neuroprotective agents and are being studied further. If these therapies interact at different points in tissue response and healing pathways following injury, it is possible that, ultimately, a "cocktail" of therapeutic agents will be used to promote optimal healing.
